# mFLUSIVA (mRNA-1010)

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mflusiva-mrna-1010
Canonical HTML page: https://getbiobrief.com/entity/mflusiva-mrna-1010

## Recent coverage (1 stories)

### Moderna's mRNA Flu Vaccine Gets FDA Greenlight—Trial Enrolled 40,805 Subjects
2026-08-06 04:49:18 · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

The U.S. FDA approved Moderna's mFLUSIVA, an mRNA seasonal influenza vaccine, for adults 50 and older. Data from two randomized trials, including a 40,805-subject Phase 3, supported the approval, with the 65+ cohort receiving accelerated approval. This milestone validates the mRNA platform beyond COVID-19 and positions Moderna to compete in the $5 billion+ global flu vaccine market.
Full story: https://getbiobrief.com/story/moderna-mflusiva-fda-approval-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.